Uranium Royalty Corp. Completes Acquisition of Additional Royalty on the Churchrock Uranium Project, New Mexico, USA
DESIGNATED NEWS RELEASE VANCOUVER, BC, Aug. 1, 2024 /PRNewswire/ – Uranium Royalty Corp. (NASDAQ: UROY) (TSX: URC) (“URC” or the “Company“)... Read more.
Servotronics Announces Death of Board Member Edward C. Cosgrove
ELMA, N.Y., Aug. 1, 2024 /PRNewswire/ — Servotronics, Inc. (NYSE American – SVT) today announced the death of Director Edward C. Cosgrove. Mr. Cosgrove... Read more.
Sunbelt Solomon Announces Acquisition of Maxima Power Group
Electrical Solutions Leader Continues Expansion into New Markets SOLOMON, Kan., Aug. 1, 2024 /PRNewswire/ — Sunbelt Solomon Services (“Sunbelt Solomon”),... Read more.
KLA Declares Regular Cash Dividend
MILPITAS, Calif., Aug. 1, 2024 /PRNewswire/ — The KLA Corporation (NASDAQ: KLAC) Board of Directors today declared a quarterly cash dividend of $1.45 per share... Read more.
Construction Partners, Inc. Completes Georgia Acquisition
Company Expands into Columbus Metro Area DOTHAN, Ala., Aug. 1, 2024 /PRNewswire/ — Construction Partners, Inc. (NASDAQ: ROAD) (“CPI” or the... Read more.
Cousins Properties and Town Lane Announce the Acquisition and Planned Modernization of Proscenium
ATLANTA, Aug. 1, 2024 /PRNewswire/ — Cousins Properties (NYSE: CUZ) and Town Lane announced today they have acquired Proscenium, a 526,000 square foot... Read more.
US LBM ACQUIRES SOUTH FLORIDA BUILDING PRODUCTS DISTRIBUTOR
National building materials distributor acquires L.D. Mullins Lumber Company RIVIERA BEACH, Fla., Aug. 1, 2024 /PRNewswire/ — US LBM, a leading distributor... Read more.
Rocket Companies Announces Second Quarter 2024 Results
Generated Q2’24 total revenue, net of $1.3 billion and adjusted revenue of $1.2 billion. Adjusted revenue exceeded the high end of guidance range and increased... Read more.
REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy... Read more.
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
– Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 – – Revumenib NDA in R/R... Read more.